Parkinson's disease and pregnancy: An updated review

Seier, Mara; Hiller, Amie

doi:10.1016/j.parkreldis.2017.05.007

Cited by 45 publications

(42 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parkinson's disease (PD) pathogenesis is a complex process, and effective treatments remain elusive till the present moment (Seier and Hiller, ). Our current study provided evidence that salidroside protects MPP + ‐induced apoptosis and oxidative stress in SH‐SY5Y cells, while theses effects were ameliorated by sirtinol, a SIRT1 activation inhibitor.…”

Section: Discussionmentioning

confidence: 99%

SIRT1 mediates salidroside‐elicited protective effects against MPP⁺‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

Wang

Sun

Wang

et al. 2017

Cell Biology International

View full text Add to dashboard Cite

Parkinson's disease (PD) is a progressive neurodegenerative disease, leading to tremor, rigidity, bradykinesia, and gait impairment. Salidroside has been reported to exhibit antioxidative and neuroprotective properties in PD. However, the underlying neuroprotective mechanisms effects of salidroside are poorly understood. Recently, a growing body of evidences suggest that silent information regulator 1 (SIRT1) plays important roles in the pathophysiology of PD. Hence, the present study investigated the roles of SIRT1 in neuroprotective effect of salidroside against N-methyl-4-phenylpyridinium (MPP þ )-induced SH-SY5Y cell injury. Our findings revealed that salidroside attenuates MPP þ -induced neurotoxicity as evidenced by the increase in cell viability, and the decreases in the caspase-3 activity and apoptosis ratio. Simultaneously, salidroside pretreatment remarkably increased SIRT1 activity, SIRT1 mRNA and protein levels in MPP þ -treated SH-SY5Y cell. However, sirtinol, a SIRT1 activation inhibitor, significantly blocked the inhibitory effects of salidroside on MPP þ -induced cytotoxicity and apoptosis. In addition, salidroside abolished MPP þ -induced the production of reactive oxygen species (ROS), the upregulation of NADPH oxidase 2 (NOX2) expression, the down-regulations of superoxide dismutase (SOD) activity and glutathione (GSH) level in SH-SY5Y cells, while these effects were also blocked by sirtinol. Finally, we found that the inhibition of salidroside on MPP þ -induced phosphorylation of p38, extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) were also reversed by sirtinol in SH-SY5Y cells. Taken together, these results indicated that SIRT1 contributes to the neuroprotection of salidroside against MPP þ -induced apoptosis and oxidative stress, in part through suppressing of mitogen-activated protein kinase (MAPK) pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

SIRT1 mediates salidroside‐elicited protective effects against MPP⁺‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

Wang

Sun

Wang

et al. 2017

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…At the 31 st week of gestation preeclampsia occurred. At the 38 th week of gestation, a cesarean delivery (cardiac deceleration at cardiotocography) resulted in the birth of a vital (Apgar score 9 and 10) low birth weight (2.440 grams) and small (for gestational age) male newborn. The infant presented with transient tachypnea and hypoglycemia in the first day after birth.…”

Section: Clinical and Biochemical Features Of The Patientmentioning

confidence: 99%

“…Pregnancy was previously reported in inherited neurotransmitter disorders with a less severe phenotype than AADC deficiency (35 women with autosomal dominant guanosine triphosphate cyclohydrolase 1 deficiency, one with dihydropterine reductase deficiency, and one with 6‐pyrovoyl‐tetrahydrobiopterin synthase deficiency) . The defect of monoaminergic neurotransmitters in AADC deficiency potentially impairs embryo‐maternal interactions at preimplantation stages of early embryogenesis, which could be prevented by the treatment with drugs acting on dopaminergic axis .…”

Section: Clinical and Biochemical Features Of The Patientmentioning

confidence: 99%

“…The defect of monoaminergic neurotransmitters in AADC deficiency potentially impairs embryo‐maternal interactions at preimplantation stages of early embryogenesis, which could be prevented by the treatment with drugs acting on dopaminergic axis . Efficacy and safety profile of pramipexole and selegiline during pregnancy and lactation are reported, in 24 and three women affected by Parkinson disease or restless legs syndrome, respectively . Pramipexole was associated with spontaneous abortion in 3 cases (co‐exposition with isotretinoin in one case) while selegiline was associated with a ventral septal defect in a twin newborn (co‐exposition with L‐DOPA/carbidopa and entacapone) …”

Section: Clinical and Biochemical Features Of The Patientmentioning

confidence: 99%

“…Efficacy and safety profile of pramipexole and selegiline during pregnancy and lactation are reported, in 24 and three women affected by Parkinson disease or restless legs syndrome, respectively . Pramipexole was associated with spontaneous abortion in 3 cases (co‐exposition with isotretinoin in one case) while selegiline was associated with a ventral septal defect in a twin newborn (co‐exposition with L‐DOPA/carbidopa and entacapone) …”

Section: Clinical and Biochemical Features Of The Patientmentioning

confidence: 99%

See 2 more Smart Citations

Successful Pregnancy in a Patient with L‐Amino Acid Decarboxylase Deficiency: Therapeutic Management and Clinical Outcome

Mastrangelo

Manti

Patanè

et al. 2018

Movement Disord Clin Pract

View full text Add to dashboard Cite

Management of Parkinson's Disease During Pregnancy: Literature Review and Multidisciplinary Input

Young

Phillips

Ebenezer

et al. 2020

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background There are no standardized clinical guidelines for the management of Parkinson's disease (PD) during pregnancy. Increasing maternal age would suggest that the incidence of pregnancy in women diagnosed with PD is likely to increase. Objective To evaluate the evidence for the treatment of PD during pregnancy and to canvass opinion from patients and clinical teams as to the optimum clinical management in this setting. Methods This involved (1) a literature review of available evidence for the use of oral medical therapy for the management of PD during pregnancy and (2) an anonymized survey of patients and clinical teams relating to previous clinical experiences. Results A literature review identified 31 publications (148 pregnancies, 49 PD, 2 parkinsonism, 21 dopa‐responsive dystonia, 32 restless leg syndrome, 1 schizophrenia, and 43 unknown indication) detailing treatment with levodopa, and 12 publications with dopamine agonists. Adverse outcomes included seizures and congenital malformations. Survey participation included patients (n = 7), neurologists (n = 35), PD nurse specialists (n = 50), obstetricians (n = 15), and midwives (n = 20) and identified a further 34 cases of pregnancy in women with PD. Common themes for suggested management included optimization of motor symptoms, preference for levodopa monotherapy, and normal delivery unless indicated by obstetric causes. Conclusions This study demonstrates the paucity of evidence for decision‐making in the medical management of PD during pregnancy. Collaboration is needed to develop a prospective registry, with longitudinal maternal and child health outcome measures to facilitate consensus management guidelines.

show abstract

Parkinson's disease and pregnancy: An updated review

Cited by 45 publications

References 45 publications

SIRT1 mediates salidroside‐elicited protective effects against MPP⁺‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

SIRT1 mediates salidroside‐elicited protective effects against MPP⁺‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

Successful Pregnancy in a Patient with L‐Amino Acid Decarboxylase Deficiency: Therapeutic Management and Clinical Outcome

Management of Parkinson's Disease During Pregnancy: Literature Review and Multidisciplinary Input

Contact Info

Product

Resources

About

Parkinson's disease and pregnancy: An updated review

Cited by 45 publications

References 45 publications

SIRT1 mediates salidroside‐elicited protective effects against MPP+‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

SIRT1 mediates salidroside‐elicited protective effects against MPP+‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

Successful Pregnancy in a Patient with L‐Amino Acid Decarboxylase Deficiency: Therapeutic Management and Clinical Outcome

Management of Parkinson's Disease During Pregnancy: Literature Review and Multidisciplinary Input

Contact Info

Product

Resources

About

SIRT1 mediates salidroside‐elicited protective effects against MPP⁺‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways

SIRT1 mediates salidroside‐elicited protective effects against MPP⁺‐induced apoptosis and oxidative stress in SH‐SY5Y cells: involvement in suppressing MAPK pathways